Author Archives: Scalper1

Baidu In For ‘Profitability Drag’ On Big O2O Spending

Baidu (BIDU) got its second price target cut in two months on Wednesday from Summit Research/W.R. Hambrecht + Co., highlighting earlier doubts that China’s search leader can dominate the increasingly competitive online-to-offline (O2O) sales arena even while spending millions to beef up its presence in that growing industry. “Currently, O2O consumers in China indulge in aggressive promotions and discounts, and we have concerns of profitability

3 Big Drugs Likely To Hit The Market Soon

Drug stocks took a pounding in the third quarter, but the leading drug companies’ pipelines have kept flowing with potentially blockbuster new drugs. Here are three key products — from Merck, Shire and Gilead Sciences — expected to be approved by the FDA in the next month or so: By Friday, Merck (MRK) is expecting to hear whether the agency will approve Keytruda for advanced non-small-cell lung cancer. Keytruda has already been on the market for a